TARRYTOWN, N.Y., Feb. 9, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that it will webcast an investor briefing on Sunday, February 13 from 9 a.m. to 10:30 a.m. Eastern Time. At the investor briefing, principal investigators from the VEGF Trap-Eye clinical studies will recap presentations from the Bascom Palmer Eye Institute's Angiogenesis, Exudation and Degeneration 2011 meeting being held in Miami, Florida on Saturday, February 12.
The investigator presentations will provide additional data from the VIEW 1 and VIEW 2 Phase 3 trials in patients with the neovascular form of age-related macular degeneration (wet AMD), the COPERNICUS Phase 3 trial in macular edema due to central retinal vein occlusion (CRVO), and the DA VINCI Phase 2 trial in diabetic macular edema (DME). Regeneron reported positive top-line results from all these trials in the fourth quarter of 2010.
"It's a privilege to be able to release this important collection of VEGF Trap-Eye data at the Bascom Palmer Eye Institute's Eighth Annual Angiogenesis Meeting," said Philip J. Rosenfeld, M.D., Ph.D., Professor of Ophthalmology, University of Miami Miller School of Medicine and Course Co-Director of the Angiogenesis 2011 Meeting. "In particular, the Phase 3 results in wet AMD suggest that the VEGF Trap-Eye has the potential to address an important unmet need of providing optimal vision gain while reducing the burden of intravitreal injections and office visits for patients and their caregivers."
The webcast and slides may be accessed through the Company's web site, www.regeneron.com, on the Investor Relations page (http://investor.regeneron.com). An archived version of the presentation will be available after the live webcast through M